Today's Daily Dose brings you news about Arena's progress in phase II study of Etrasimod in ulcerative colitis; expanded FDA approval of Bristol-Myers' leukemia drug Sprycel; voluntarily delisting of Mylan's ordinary shares from the Tel Aviv Stock Exchange and Vanda's disappointment over Fanaptum's failure to win the CHMP's backing.
from RTT - Biotech http://ift.tt/2ml85nh
via IFTTT
No comments:
Post a Comment